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Abstract 
Background and Aim: Alteplase is a thrombolytic drug that is produced by recombinant DNA technology. Tissue 
plasminogen activator enzyme which converts plasminogen to the active form of plasmin is also produced by the same 
technology; it causes fibrinolysis and clot dissolution. This study aimed to compare the efficacy and complications of 
Alteplase injection in patients with acute ischemic stroke (AIS( during the first 3 hours and  3-4.5 hours after the onset 
of symptoms. 
Methods: In this study, patients with AIS who were referred to Golestan Hospital of Ahvaz city during 2018-2019 
were selected. Information was collected by a checklist.  
Results: The results showed that the mean Modified Rankin Scale (mRS) for 3 months and 6 months (p-value: 0.91 
for 3 months and p-value: 0.80 for 6 months) and National Institutes of Health Stroke Scale (NIHSS) (p-value: 0.21) 
were not significantly different between both groups; statistically, no significant relationship was observed between 
them. The incidence of complications after treatment was almost similar, in both groups.  
Conclusion: Finally, it was concluded that complications and efficacy of rt-PA (Alteplase) injection were not 
statistically different, between the two groups under study. 
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Stroke is the third leading cause of death and the 
most common debilitating neurological disease (1). 
Ischemia causes neuronal damages and clinical 
symptoms due to the deprivation of brain tissue in 
the use of oxygen and glucose as well as metabolic 
products; if it prolongs, permanent and irreversible 
neurological damages occur (2). Despite the high 
prevalence and debilitating effects of stroke, many 
preventive strategies have been designed. Different 
treatments for patients are also considered, based on 
the involved mechanisms of pathogenesis (3). The 
most important treatments include the use of 
antiplatelet drugs, anticoagulants, and 
thrombolytics. The use of these drugs has been able 
to prevent the progression of the disease to a large 
extent and improve the clinical symptoms of 
patients; however, their clinical side effects are a 
serious problem that can disrupt the treatment 
process (4). 
Alteplase is a recombinant tissue plasminogen 
activator (rt-PA) is a recombinant thrombolytic 
drug that causes thrombolysis by activating 
plasminogen; today, it is prescribed for patients 
with stroke. Although many studies have been 
performed about treatment aspects of the Alteplase,  
a few pieces of research have been done about its 
efficacy and the side effects (5, 6). Therefore, in 
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this study, we evaluated the efficacy and side 
effects of Alteplase usage in patients with stroke.  
Methods 
This observational cohort study evaluated the 
patients with acute ischemic stroke (AIS) who were 
referred to Golestan Hospital of Ahvaz city, during 
2018-2019. Based on the interval between the onset 
of symptoms and referral to the emergency 
department of a hospital, patients were categorized 
into two groups; group 1, included patients who 
referred during the first 3 hours after Symptom 
onset (n=64), and group 2 the patients who referred 
within 3.5-5 hours after the onset of symptoms 
(n=23). rt-PA injection was done for both groups of 
individuals. Patients with AIS were diagnosed 
according to the AHA\ASA2018 guideline; the 
treatment outcomes and complications were 
compared between the two groups. 
After explaining how to conduct the research and 
the study objectives, the informed consent was 
signed by patients or their companions. Inclusion 
criteria included age over 18 years, the onset of 
symptoms in the last 4.5 hours, and ischemic stroke 
symptoms. Exclusion criteria were as follows, 
gastrointestinal or urinary bleeding in the past 
21 days, severe head trauma in the past 3 months, 
Xa inhibitor and low molecular heparin (LMH) 
intake in the last 24 hours, and intraracial 
intracranial tumor. Patients’ information included 
demographic characteristics (age, gender), stroke 
risk factors (hypertension history, diabetes, 
hypertension, smoking, alcohol or drug use, 
ischemic heart disease, and history of stroke), blood 
pressure, and blood sugar. CT scan result, time to 
onset of symptoms (event to needle), National 
Institutes of Health Stroke Scale (NIHSS) score at 
baseline were recorded in the pre-designed 
checklist.  
Patients were selected for thrombolytic treatment 
and tPA injection based on the AHA/ASA 2018 
guideline. tPA was administered at a dose of 0.9 
mg/kg and 10% as a bolus, and the rest was infused 
continuously for 1 hour. Then, the following 
information was recorded, NIHS score 24 hours 
after treatment, complications including 
symptomatic or asymptomatic intracerebral 
hemorrhage, bleeding in other organs, pneumonia, 
cardiovascular complications, embolism, allergic 
reaction, and mortality during hospitalization. Also, 
3 months and 6 months after admission, the patient 
or his companions were contacted by phone, and 
the Modified Rankin Scale (mRS) and the incidence 
of morbidity and mortality were evaluated in both 
groups.  
Statistical Analysis 
In quantitative variables, mean or median was used 
to describe the data center; standard deviation (SD) 
or mid-quarter amplitude was used to describe the 
data scatter. Frequency and percentage were used in 
the qualitative variables. Kolmogorov-Smirnov test 
and quadratic-multiple diagram were applied to 
check the data normality. For univariate data 
analysis, the Chi-square test, Fisher's exact test, 
independent t-test, Mann-Whitney test, and 
univariate Cox regression were used. The 
significance level was considered as 0.05. All 
analyzes were performed using SPSS software 
version 22.  
Results 
After selecting patients, 64 of them were treated 
with rt-PA within three hours after the onset of 
symptoms; 23 individuals received rt-PA about 4.5-
5 hours after the onset of symptoms, too. Patient 
demographic information has been listed in Table 1. 
Accordingly, no significant relationship was 
observed for the studied variables between the two 
groups.  
However, the length of hospital stay was longer in 
the group which received the drug during the first 
three hours after the onset of symptoms; the 
difference was not statistically significant (p-
value=0.857) (Table 1). 
In the first group, 3.1% of treated patients with rt-
PA developed symptomatic cerebral hemorrhage as 
a complication of thrombolytic therapy. In the other 
group, 8.7% of patients had an asymptomatic 
cerebral hemorrhage, which was not statistically 
significant (p-value=0.284).  
Asymptomatic cerebral hemorrhage after treatment 
was detected in 12.5% of the patients who were 
categorized in the first group.  This complication 
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did not occur in the patients who received the drug 
during 4.5-5 hours after the onset of symptoms. 
However, the difference was not statistically 
significant between the two groups (p-
value=0.103). 
Table1. Demographic information of patients 
Abbreviation: BP: Blood pressure, NIHSS: National Institutes of Health Stroke Scale, HTN: Hypertension, ACA: Anterior 
Cerebral Artery, MCA: Middle Cerebral Artery, PCA: Posterior Cerebral Artery. 
In addition, 25% of patients in the first group 
experienced other complications (subarachnoid, 
epidural, subdural hemorrhage, extracranial 
hemorrhage, embolism, allergic reaction, Petechia, 
pneumonia, arrhythmia, and myocardial infarction); 
p-value > 𝟑 𝐡𝐨𝐮𝐫𝐬 ≤ 𝟑 𝐡𝐨𝐮𝐫𝐬 Variables 
0.709 66.57±12.73 67.75±13.12 Age (years) 
0.663 
12(52.2) 30(46.9) Women 
Sex 
11(47.8) 34(53.1) men 












Blood Sugar (mg/dl) 
0.922 15.13±7.32 14.97±6.59 NIHSS 
0.857 7.05±4.08 8.49±5.52 Days of Hospitalization 
0.492 
9(39.1) 20(31.3) No 
HTN 
14(60.9) 44(68.8) Yes 
0.267 
17(73.9) 54(84.4) No 
Smoking 
6(26.1) 10(15.6) Yes 
0.648 
18(78.3) 47(73.4) No 
Diabetes 
5(21.7) 17(26.6) Yes 
0.720 
21(91.3) 55(85.9) No 
Atrial fibrillation 
2(8.7) 9(14.1) Yes 
1 
22(95.7) 62(96.9) No 
Vasculitis 
1(4.3) 2(3.1) Yes 
1 
19(82.6) 51(79.7) No 
Hyperlipidemia 
4(17.4) 13(20.3) Yes 
0.461 
22(95.7) 63(98.4) No 
Previous stroke 
1(4.3) 1(1.6) Yes 
0.799 
17(73.9) 49(76.6) No 
Congestive heart failure 
6(26.1) 15(23.4) Yes 
0.569 
23(100) 60(93.8) No 
Use of anticoagulation 
0(0) 4(6.3) Yes 
0.720 
21(91.3) 55(85.9) No 
ACA 
2(8.7) 9(14.1) Yes 
0.541 
20(87) 50(78.1) No 
MCAstem 
3(13) 14(21.9) Yes 
0.214 
16(69.6) 35(54.7) No 
MCA superior 
7(30.4) 29(45.3) Yes 
0.220 
11(47.8) 40(62.5) No 
MCAinferior 
12(52.2) 24(37.5) Yes 
0.461 
22(95.1) 63(98.4) No 
Lacunar 
1(4.3) 1(1.6) Yes 
0.694 
19(82.6) 58(90.6) No 
PCA 
2 (17.4) 6(9.4) Yes 
Comparison of Efficacy and Complication of Alteplase …                                                                  Amirazodi E, et al. 
Archives of Medical Laboratory Sciences; Volume 7, 2021 (Continuous Volume)  4 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License 
the incidence of these complications was 13% in the 
second group.  
Statistical analysis showed no significant 
differences between the studied groups (p-
value=0.378) (Table 2). 
 
Table2. Related side effects of rt-PA injection after the treatment in patients 
Univariable 
 
p-value > 𝟑 𝐡𝐨𝐮𝐫𝐬 ≤ 𝟑 𝐡𝐨𝐮𝐫𝐬 
0.284 
21(91.3) 62(96.9) No 
Symptomatic ICH 
2(8.7) 2(3.1) Yes 
0.103 
23(100) 56(87.5) No 
Asymptomatic ICH 
0(0) 8(12.5) Yes 
0.378 
20(87) 48(75) No 
Other side effects* 
3(13) 16(25) Yes 
ICH: Intracerebral hemorrhage. * Subarachnoid hemorrhage, epidural, subdural, extracranial hemorrhage, embolism, allergic 
reaction, petechia, pneumonia, arrhythmia, and myocardial infarction.  
 
Patients were divided into two groups in terms of 
mRS score with favorable (score zero and one) and 
unfavorable outcomes (score 2, 3, 4, 5, and 6). 
Statistical evaluation of mRS score including the 
calculation of OR and CI was done, at the times 
three and six months after treatment in the patients 
of the two groups; no statistically significant 
difference was found between the groups. The 
results are shown in Table 4.  
Comparison of Hazard Ratio (HR) showed a similar 
risk between the two groups in terms of mortality 
during hospitalization up to six months and after 
thrombolytic therapy (Table. 3). 
Table3. Mortality-derived treatment in patients 
Multivariable Univariable 
 
p-value 95%CI HR p-value 95%CI HR 
0.696 (0.15 − 17.60) 1.61 0.818 (0.23 −  6.30) 1.21 Time(≥ 𝟑 𝐡 𝐭𝐨 < 𝟑 𝐡) 
Table 4. mRS score at 3 and 6 months after acute stroke in patients. 
Multivariable Univariable 
 
p-value 95%CI OR p-value 95%CI OR 
0.911 (0.15 −  5.57) 0.90 0.955 (0.24 −  4.58) 1.04 mRS 3month 
0.809 (0.14 −  4.76) 0.80 0.926 (0.26 −  4.31) 1.07 mRS 6month 
mRS: modified Rankin scale 
 
It was also found that the mean NIHSS before 
treatment was lower in the patients of group one, 
but this difference was not statistically significant 
(p-value = 0.922). After treatment, the mean NIHSS 
was 10.55±7.76  in the first group, and it was 
11.83±9.44  in the other; it was not statistically 
significant, too (Table.5).  
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Table 5. Mean NIHSS score after treatment in patients. 
Multivariable Univariable 
 
p-value 95%CI B p-value > 𝟑 𝐡𝐨𝐮𝐫𝐞 ≤ 𝟑𝐡𝐨𝐮𝐫𝐞 
0.212 (−0.91 − 4.04) 1.56 0.524 11.83±9.44 10.55±7.76 NIHS Score 
 
Discussion 
The side effect of rt-PA in patients with AIS is 
highly time-dependent (7). Extending the time for 
intravenous rt-PA in patients with AIS is an 
important strategy in stroke patients' thrombolytic 
therapy (8). Rapid administration of rt-PA after 
stroke improves the outcomes of patients' clinical 
conditions (9). In a study, the rate of patients treated 
with IV rt-PA during the first 3 hours and 4.5 hours 
was examined; it was found that the majority of 
patients were treated within 0-3 hours but 
increasing the duration to 3-4.5 hours does not 
appear to affect patient outcomes adversely (10). In 
the present study, the results showed that the mean 
NIHSS after treatment was lower than before, in 
both groups. However, the mean NIHSS after 
treatment in both groups was almost the same. 
Therefore, no statistically significant relationship 
was observed between them. Also, the mean score 
of mRS was similar in both groups and no 
significant difference was observed between them. 
Symptomatic Cerebral hemorrhage in the patients 
treated with rt-PA about 3 hours after the onset of 
symptoms (3.1% ) was less than the other group 
(8.7%,); it was not statistically significant (p-value 
= 0.284). This result indicates the importance of 
diagnosing the signs and symptoms of a stroke by 
patients or their families and getting the patient to 
the hospital quickly. Also, Shobha et al. examined 
the effect of thrombolytic therapy on patients with 
AIS; they reported that rt-PA intake increased 
symptomatic intracerebral hemorrhage 
significantly, in individuals who received the drug 
during 3–4.5 hours compared to ones who received 
within 0–3 hours  (11). As these results, Xu et al.'s 
study showed that the rate of asymptomatic cerebral 
hemorrhage within 24-36 hours, mortality rate, and 
NIHSS were not significantly different between the 
two groups (0–3 and 3–4.5 hours) (7). In line with 
this study, asymptomatic cerebral hemorrhage was 
found in 12.5% of treated patients with rt-PA about 
3 hours after the onset of symptoms, but it did not 
occur in the other group; no evidence was found to 
confirm the significant statistical difference 
between the two groups. 
Hacke et al. examined the effect of Alteplase and 
placebo 3-4.5 hours after AIS; they showed that 
intracranial hemorrhage was significantly greater in 
Alteplase receivers (12). Clark et al. evaluated the 
effect of rt-PA during 3 and 5 hours after symptom 
onset, in a clinical trial study. They stated that the 
symptomatic intracerebral hemorrhage rate 
increased significantly within the first 10 days of 
treatment with rt-PA (13). In this study, 25% of rt-
PA treated patients during the first 3 hours after the 
onset of symptoms, and 13% of the subjects in the 
other group experienced the subarachnoid, epidural, 
subdural hemorrhage, extracranial hemorrhage, 
embolism, allergic reaction, petechia, pneumonia, 
arrhythmia, and myocardial infarction.  
Conclusion 
The present study showed that rt-PA prescription after 
3 hours from the onset of symptoms is not much 
different in terms of complications occurrence, in 
comparison to patients with AIS who receive drug 
earlier. Therefore, it is better to focus on this issue in 
future studies. We recommend a survey in the larger 
population. Therefore, to confirm a definite 
achievement, other centers should perform similar 
studies in the field of thrombolytic treatment of 
patients with AIS. 
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